Ginkgo Bioworks

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.

Proof Diagnostics is a life sciences company focused on developing diagnostic tools and therapeutic applications. It specializes in creating rapid diagnostic tests, including those for detecting infectious diseases such as coronavirus. The company offers diagnostic kits that enable medical professionals to test patients efficiently, enhancing the ability to identify infections quickly. Additionally, Proof Diagnostics is working on a smart, portable system aimed at improving the detection of various infectious diseases, thereby contributing to advancements in public health and disease management.

Patch Biosciences specializes in the development of machine-designed DNA for gene therapy, leveraging synthetic biology and machine learning. The company has created a platform that engineers genetic medicine vehicles aimed at being effective, specific, and durable, with the potential to target a wide array of diseases. By employing large-scale DNA synthesis, Patch Biosciences aims to enhance the safety and efficacy of gene therapies, ultimately contributing to advancements in healthcare and addressing diverse medical needs.

Reverie Labs is a Boston-based company focused on improving drug development processes for pharmaceutical firms through advanced machine learning techniques. The company utilizes these algorithms to predict the bio physicochemical properties of drug candidates, thereby accelerating preclinical development. Reverie Labs specializes in lead generation and optimization by creating structure-based predictive models that assess the potency of small molecules. It also offers a multi-objective molecular optimizer that generates new molecules while ensuring they maintain both potency and synthesizability. This approach allows for the prioritization and optimization of drug candidates, facilitating their progression to animal and human clinical trials more efficiently.

Altar is a biotechnology company focused on automated fluidics, dedicated to enhancing the performance of microorganisms for commercial applications. They develop proprietary technologies that utilize automated cultivation devices to harness natural selection, allowing for the continuous and contamination-free proliferation of cell suspensions. This innovative approach enables industries to improve the efficacy of microorganisms used in producing food, feed, flavors and fragrances, cosmetics, fuels, chemicals, and health products. By ensuring 24/7 operation, Altar's technology supports the long-term cultivation of microbes, making it a valuable resource for various sectors seeking to optimize their microbial applications.

Circularis Biotechnologies, Inc. is a biotechnology company focused on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Founded in 2014 and based in Oakland, California, the company offers a range of products and services, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. Additionally, Circularis provides services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its technology, Circularis Biotechnologies seeks to advance the capabilities of biotherapeutic production in the industry.

Zymergen, Inc. is a biotechnology company based in Emeryville, California, established in 2013, with additional offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan. The company focuses on researching, developing, and manufacturing microbes for a variety of sectors, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. Zymergen employs a platform that integrates automation, machine learning, and genomics to enhance the optimization of microbial strains, improve existing production processes, and bridge the gap between lab and commercial manufacturing. Additionally, the company offers services for new product development, leveraging its expertise to engineer novel molecules from microbes, thereby harnessing the potential of biological innovation to create advanced materials and products across multiple industries.

Phytolon Ltd, founded in 2000 and based in Misgav, Israel, specializes in the development of natural food colorants. The company has established a novel and sustainable technology that utilizes fermentation processes with baker’s yeast cells as biofactories to produce high-quality, plant-based food colors. This innovative approach provides a healthy alternative to synthetic food dyes, offering food manufacturers safe, cost-effective, and stable all-natural colors. Phytolon is dedicated to promoting human health and environmental sustainability through scientific advancement in the food color industry.

Bitome is a two-year-old, Boston-based connected med device company. Its first product is a noninvasive tool for monitoring hydration status with broad applications across the dialysis, diabetic, sports performance, and maternal / fetal monitoring spaces. In a first application, Bitome’s technology will precisely assess volume status in congestive heart failure (CHF) patients – a key, but hard to measure, biometric correlated with patient outcomes. In short, Bitome wants to use hydration monitoring technology to do for CHF, what glucose monitoring has done for diabetes.

FGen is a Swiss start-up company founded 2011 in Basel as a spin-off from the Department of Biosystems Science and Engineering of the ETH Zurich. As a contract reasearch organization we collaborate with partners from Biotech, Life Sciences, and Pharma in order to establish efficient bioprocesses and to develop new biopharmaceuticals.

Project Beacon COVID-19 is a social benefit organization based in Massachusetts focused on enhancing the capacity, availability, accessibility, and affordability of COVID-19 testing. The organization provides a range of services, including the evaluation of various testing strategies for organizations, managing test logistics, and establishing sample collection sites. Additionally, Project Beacon assists in reporting test results to individuals, organizations, and public health authorities. By facilitating these services, the organization aims to support the safe reopening of society and the return to work, while also addressing disparities in access to testing across the state.

Cambium develops biomaterials for fields such as defense, space transport, aerospace, and renewable energy. Leveraging the Deep Tech convergence between synthetic biology, materials science, computation & automation, it delivers changes in advanced material performance and sustainability to improve products.

Dutch DNA is a technology provider specializing in the food, feed, and enzyme industries. The company operates as a contract manufacturing organization, focusing on the development of fungal strains and fermentation processes for protein and organic acid production. It is dedicated to creating tailored biotechnology solutions based on client requirements, offering a platform that facilitates the discovery and production of enzymes and metabolites. This enables medical enterprises to achieve high purity and low production costs in their processes.

Novogy, Inc. is focused on developing bio-based solutions for the production of food, fuel, and chemicals, with a particular emphasis on cellulosic biofuels derived from waste paper sludge. The company employs an innovative technology that integrates molecular biology and process engineering to enhance competitiveness in production processes while minimizing antibiotic use in large-scale operations. Serving various bio-based industries, Novogy distributes its cellulosic biofuels primarily for the transportation sector. Established in 2009 and headquartered in Cambridge, Massachusetts, Novogy operates as a subsidiary of TOTAL S.A.

Allonnia LLC, based in Boston, Massachusetts, specializes in waste remediation services through the development of innovative enzymes, proteins, and microbes that can degrade or metabolize contaminants. Founded in 2019, the company focuses on extracting value from waste by creating solutions that transform waste into usable materials, addressing critical environmental issues such as water safety and CO2 reduction. Allonnia’s unique biotechnology approach has garnered industry recognition, including multiple accolades as a Great Place to Work and nominations for various innovation awards. Their commitment to sustainability positions them as a leader in providing environmentally friendly solutions for waste management and resource recovery.

Warp Drive Bio, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on developing genomic technology to discover drugs of natural origin. Founded in 2010, the company utilizes a proprietary genomic search engine and customized search queries to uncover hidden natural products by analyzing their unique genomic signatures. This innovative approach allows researchers to generate novel drug candidates and understand their mechanisms of action, facilitating the conversion of genomic data into potential therapeutic drugs. As of October 2018, Warp Drive Bio operates as a subsidiary of REVOLUTION Medicines, Inc.

Genomatica, Inc. is a biotechnology company based in San Diego, California, that specializes in developing manufacturing processes to produce intermediate and basic chemicals from renewable feedstocks. Utilizing a proprietary platform, the company creates fermentation-based processes and engineers microorganisms that facilitate the conversion of these feedstocks into valuable chemicals. Genomatica has commercialized processes for butanediol, used in biodegradable plastics and apparel, and butylene glycol, which is utilized in cosmetics and personal care products. The company is also advancing the development of bio-nylon and has a pipeline targeting the production of 20 different chemicals, including butadiene. Recognized for its innovative technology, Genomatica has received several awards, including the Kirkpatrick Award for notable chemical engineering advancements and the ICIS Innovation Award for its Brontide butylene glycol.

Joyn Bio is a joint venture founded by Bayer and Ginkgo Bioworks developing probiotics for plants to provide growers with next generation solutions to their biggest challenges. Joyn Bio’s first area of focus will be on engineering microbes that provide cereal crops with their nitrogen needs to reduce agriculture’s reliance on nitrogen fertilizer and its environmental impact. Joyn Bio brings together microbiologists, synthetic biologists, plant scientists, and ecologists at its headquarters in Boston, Massachusetts and its plant research facility in West Sacramento, California.

Gen9 is a privately held company based in Cambridge, Massachusetts, focused on advancing synthetic biology to enhance the production of DNA content. Established in 2009 by experts in the field, Gen9 has developed a next-generation gene synthesis technology that enables high-throughput, automated DNA construct production with improved cost efficiency and accuracy compared to traditional methods. The company's innovations aim to support various industries, including enzyme and chemical production, pharmaceuticals, and biofuels, by facilitating the constructive application of synthetic biology techniques to improve genes, pathways, genomes, and organisms.